Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) have received a consensus recommendation of “Buy” from the twenty-two ratings firms that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and eighteen have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $90.36.
ONCE has been the topic of several research reports. Royal Bank Of Canada restated a “buy” rating on shares of Spark Therapeutics in a research note on Wednesday, October 25th. Cantor Fitzgerald restated a “buy” rating on shares of Spark Therapeutics in a research note on Friday, August 25th. Raymond James Financial, Inc. initiated coverage on Spark Therapeutics in a research note on Thursday, October 12th. They set an “outperform” rating and a $96.00 price objective on the stock. Chardan Capital upgraded Spark Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $60.00 to $100.00 in a research note on Tuesday, August 8th. Finally, BidaskClub upgraded Spark Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, August 26th.
Shares of Spark Therapeutics (NASDAQ:ONCE) traded up $0.85 during midday trading on Thursday, reaching $73.93. The company’s stock had a trading volume of 340,947 shares, compared to its average volume of 501,876. Spark Therapeutics has a 12-month low of $47.03 and a 12-month high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. During the same quarter in the previous year, the company earned ($1.07) EPS. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. equities research analysts expect that Spark Therapeutics will post -7.6 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Analysts Set Spark Therapeutics, Inc. (ONCE) Target Price at $90.36” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/05/analysts-set-spark-therapeutics-inc-once-target-price-at-90-36.html.
In related news, insider Barge Joseph La sold 5,500 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $71.44, for a total value of $392,920.00. Following the completion of the transaction, the insider now directly owns 8,146 shares of the company’s stock, valued at approximately $581,950.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jeffrey D. Marrazzo sold 21,350 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $80.01, for a total value of $1,708,213.50. Following the completion of the transaction, the chief executive officer now directly owns 251,350 shares of the company’s stock, valued at $20,110,513.50. The disclosure for this sale can be found here. Insiders sold a total of 1,099,659 shares of company stock valued at $92,457,658 over the last three months. Corporate insiders own 7.30% of the company’s stock.
A number of hedge funds have recently modified their holdings of ONCE. Principal Financial Group Inc. grew its holdings in Spark Therapeutics by 0.3% in the 1st quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock worth $2,067,000 after buying an additional 122 shares in the last quarter. Teachers Advisors LLC grew its holdings in Spark Therapeutics by 1.9% in the 1st quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock worth $1,842,000 after buying an additional 650 shares in the last quarter. Vanguard Group Inc. grew its holdings in Spark Therapeutics by 5.2% in the 1st quarter. Vanguard Group Inc. now owns 1,827,660 shares of the biotechnology company’s stock worth $97,487,000 after buying an additional 90,686 shares in the last quarter. Geode Capital Management LLC grew its holdings in Spark Therapeutics by 4.9% in the 1st quarter. Geode Capital Management LLC now owns 177,154 shares of the biotechnology company’s stock worth $9,449,000 after buying an additional 8,284 shares in the last quarter. Finally, BlackRock Inc. grew its holdings in Spark Therapeutics by 11,332.0% in the 1st quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock worth $98,158,000 after buying an additional 1,824,117 shares in the last quarter. 79.49% of the stock is owned by institutional investors and hedge funds.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.